IMPORTANT INFORMATION

•Your Innovo® insulin doser is designed to work accurately and safely. Innovo® has built-in safety features to ensure that the insulin dose injected is the dose that has been dialled. In the unlikely event of a malfunction your Innovo® doser will lock to prevent you from receiving a wrong dose.

•As a precautionary measure, always carry a spare insulin delivery device in case your Innovo® is lost or damaged.

•A flashing display tells you that battery power is low. Be sure to replace Innovo® within 30 days. The battery cannot be changed. This is to guarantee quality and safety at all times. Contact your supplier to get a new Innovo®.

•Innovo® is tough but could still be damaged. So handle it with care, do not drop it and avoid knocking it against hard surfaces. If Innovo® has

been dropped or knocked, you must carry out a function check

(see page 23).

•Never use your Innovo® unless you are sure that it is working properly.

•Always replace the cap after using Innovo®.

•Do not play with the dose selector or the push button as this can cause Innovo® to wear out.

•Keep Innovo®, Penfill® and NovoFine® out of the reach of children.

•Your Innovo® is for use by you alone. Do not allow anyone else to use it.

•Health care professionals, relatives and other carers should follow general precautionary measures for removal and disposal of needles to eliminate the risk of unintended needle penetration.

33

Page 36 Page 38
Page 37
Image 37
Novo Nordisk 510620 manual Important Information
Page 36 Page 38

510620 specifications

Novo Nordisk 510620 is a cutting-edge medication developed by the renowned healthcare company Novo Nordisk, which specializes in diabetes care and other chronic diseases. As a part of Novo Nordisk's innovative product portfolio, 510620 is particularly aimed at addressing the needs of patients with type 2 diabetes, a condition that affects millions worldwide.

One of the main features of Novo Nordisk 510620 is its formulation as a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone that plays a crucial role in glucose metabolism. By mimicking the action of this hormone, 510620 stimulates insulin secretion in response to meals, inhibits glucagon release, and promotes satiety. This multi-faceted approach not only helps in lowering blood sugar levels but also aids in weight management, making it particularly suitable for overweight individuals with type 2 diabetes.

In terms of technology, Novo Nordisk 510620 utilizes a novel delivery system that enhances the bioavailability and stability of the active ingredient. This innovative technology involves an injectable formulation that is designed for easy administration, with pre-filled pens that allow patients to self-inject the medication comfortably. The convenience of the delivery system assists in improving patient adherence to treatment protocols, an essential factor in managing chronic conditions such as diabetes.

Another characteristic of Novo Nordisk 510620 is its cardiovascular benefits. Clinical studies have shown that patients using this medication not only achieve better glycemic control but also experience a reduction in the risk of major cardiovascular events. This attribute is critical, considering the high prevalence of cardiovascular complications associated with diabetes.

Safety and tolerability are also key aspects of Novo Nordisk 510620. The medication has undergone rigorous clinical trials, which have demonstrated a favorable safety profile, with common side effects being mild to moderate. Regular monitoring and education about potential side effects play a vital role in ensuring that patients can use 510620 effectively.

In summary, Novo Nordisk 510620 represents an advanced treatment option for type 2 diabetes, characterized by its GLP-1 receptor agonist activity, innovative delivery technology, cardiovascular benefits, and strong safety profile. By continually working on research and development, Novo Nordisk aims to improve the quality of life for individuals affected by chronic diseases, making substantial contributions to the field of diabetes management.
Top Page Image Contents